Argatroban Plus R-tPA for Acute Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 808 participants.

Also called NCT03740958

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 808 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03740958
Other papers using this trial's data
  • Circadian Rhythm and Efficacy of Argatroban in Ischemic Stroke with Alteplase: A Post Hoc Analysis of the ARAIS Trial CNS drugs, 2026-05 DOI, PubMed 41678142
  • Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial JAMA, 2023-02-28 DOI, PubMed 36757755, PMC9912168 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03740958. Randomized; no masking; primary purpose treatment. Start 2018-12-21 (actual); primary completion 2022-01-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Argatroban Plus R-tPA for Acute Ischemic Stroke
Condition
Stroke
Intervention (Drug)
rt-PA
Intervention (Drug)
Argatroban
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct03740958
Content hash
c952bbd0d98659c3e0d848b1bcf5f3a0e91c13e78ebd93502d6c844cd41c9bd5